Full-Time
Process Engineer
Posted on 2/5/2025
Medline
10,001+ employees
Manufacturer and distributor of medical supplies
Compensation Overview
$77.5k - $112.3k/yr
No H1B Sponsorship
Austell, GA, USA
In Person
 Process Engineering |
|---|
- Bachelor’s degree in an Engineering discipline.
- At least 2 years engineering experience.
- Technical writing, research paper writing, and/or experimental design experience.
- ERP systems knowledge and experience.
- Intermediate skill level in computer and systems use (Microsoft Word, PowerPoint, and Excel).
- Analyze, review, and recommend technological solutions and innovative techniques to reduce Medline’s expenses and improve cost structure while maintaining or improving quality.
- Lead multiple medium scale projects from concept to realization involving individuals from multiple departments and disciplines.
- Develop basic to medium sized project plans. These plans will include action steps, schedules, etc. to enhance ability to deliver quality projects on-time and within budget. Develop and write functional requirements, test plans, and work with production issues.
- Conduct training, when appropriate, on quality assurance and/or engineering concepts and tools, including but not limited to inspection, measurement and test methods.
- Utilize warehouse management and labor management systems.
Medline Industries designs, produces, and distributes medical supplies for healthcare settings. It combines manufacturing and distribution to control product quality and sell directly to hospitals and other healthcare providers, offering a wide range of Medline-branded and third-party products. Its products include gowns, uniforms, gloves, and other medical consumables, produced and then delivered through a direct-to-provider model. The company differentiates itself with vertical integration that bypasses traditional distributors, a long-standing family-led culture that continued after a 2021 private-equity-led majority investment, and the scale to serve healthcare systems with a broad catalog. The goal is to supply healthcare providers with a comprehensive, high-quality catalog of medical products while expanding market reach and maintaining reliability through direct manufacturing-and-distribution control.
Company Size
10,001+
Company Stage
IPO
Headquarters
Northfield, Illinois
Founded
1966
Your Connections
People at Medline who can refer or advise you
Simplify's Take
What believers are saying
- Medline launches co-branded anti-thrombogenic catheters with Access Vascular in the $600M market, available late 2026[1][2].
- Medline expands Slovakia manufacturing facility to double European capacity, with production starting in 2027[1][5].
- Medline completed $2B notes offering and $2.75B loan refinancing in 2026, extending maturities to 2031–2033[1][6].
What critics are saying
- FDA Class I action and shipment ban likely from B. cereus contamination at Waukegan facility within 3–6 months[1][2].
- Loss of Prime Vendor contracts and hospital exclusivity probable due to two FDA warnings signaling systemic quality failure[1][7].
- Competitors MGS and TekniPlex in Slovakia may accelerate EMEA market takeout by leveraging Medline's regulatory turmoil[1][5].
What makes Medline unique
- Medline uses vertical integration to control quality and sell directly to hospitals, bypassing traditional distributors[1][2].
- Medline offers a hybrid model of manufacturing and distributing medical supplies, strengthening supply chain resilience[1][3].
- The Mills family remains the largest shareholder post-acquisition, preserving long-standing culture while gaining expansion resources[1][4].
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Highest FDA recall issued for certain catheters, heart pump controllers. Jun 23, 2026 - 03:50 PM The Food and Drug Administration has identified a Class I recall of reprocessed electrophysiology and ultrasound catheters by Medline Industries due to specific lots potentially containing small residual particles. The FDA said that all affected products should be destroyed after recall response actions are complete. The agency also identified a Class I recall of all Automated Impella Controllers by Abiomed due to the potential of an internal software error when a patient experiences a period longer than 80 minutes with no residual pulsatility. The Abiomed recall involves updating use instructions and does not involve removing them from where they are used or sold. The FDA also issued an early alert for catheter introducer kits by Abiomed and Oscor due to a potential for introducer sheath leakage.
Medline draws another US FDA warning in two months over quality lapses. By Thomson Reuters Jun 3, 2026 | 9:39 AM June 3 (Reuters) - The U.S. FDA issued a warning letter to medical device maker Medline over violations of manufacturing quality standards, the second such action against the company in two months. The Food and Drug Administration, in its letter dated May 28, said the company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices. This follows an FDA warning letter in April that flagged defects in Medline's syringes used in heart procedures and warned of enforcement action if the issues were not addressed. In its latest letter, the FDA said Medline's probe into the contaminated samples was inadequate and faulted the company for not explaining why earlier corrective actions had failed, warning that such lapses may pose a patient safety hazard. "Following an inspection of our ReadyCare Waukegan facility (in Illinois), we implemented significant improvements in our production processes and plant operations to ensure the highest levels of quality," the company said in an emailed response. The FDA has directed Medline to provide an independent risk assessment of all contamination hazards in its manufacturing processes, equipment and facilities, along with a remediation plan and timelines. The regulator said Medline's manufacturing operators have routinely deviated from cleaning and disinfection procedures, and also flagged manufacturing lapses at other facilities in the company's network. It added that "repeated failures at multiple sites" demonstrate inadequate management oversight and control, and said the company should assess its operations to ensure they conform to FDA requirements. The company said it is continuing to fully engage with the FDA related to both its Waukegan facility and its other drug manufacturing sites. Failure to address this matter may result in regulatory or legal action, the FDA said. The company must respond within 15 days of receiving the letter. (Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)
Woman's Hospital selects Medline as its laboratory Prime Vendor. May 18, 2026 - Medline announced that it signed an expanded Prime Vendor agreement with Baton Rouge-based Woman's Hospital, which specializes in high-quality care for women and infants and is the largest delivery service in Louisiana and among the largest in the nation. The hospital provides maternity care, infant care, maternal mental health care and cancer treatment to patients across the state. With this new agreement, Woman's Hospital will have access to Medline's comprehensive portfolio of laboratory products, in addition to medical-surgical products. The agreement also provides access to Medline's distribution capabilities to help support more efficient ordering, improved inventory visibility and reliable delivery.
Medline neurosurgical sponge recall: A Staritas resource to support informed substitution decisions. On March 13, 2026, Medline announced a voluntary recall of its neurosurgical sponges due to elevated endotoxin levels. All affected products must be destroyed, and there is currently no timeline for return, creating an immediate supply disruption for providers that rely on these sponges for critical procedures. Neurosurgical sponges are essential in delicate operations where sterility, precision, and absorbency are non-negotiable. This recall presents more than a sourcing challenge. Clinical teams must rapidly evaluate alternatives, supply chain leaders must secure inventory in a constrained market, and finance teams must manage pricing volatility, all while ensuring continuity of care. To support providers navigating this disruption, Staritas has developed a Functional Equivalence Report identifying U.S. alternatives to the recalled Medline products. The report goes beyond a substitute list by offering structured comparisons across key clinical specifications such as size, materials, absorbency, and intended use. This approach helps teams assess safety and performance with confidence. The report also includes Supply Guide price benchmarks, giving supply chain and finance leaders critical visibility into market pricing at a time when demand shifts and cost pressures are high. Together, these insights empower faster, more informed decision-making, strengthen cross-functional alignment, and help make every choice clear. While recalls are disruptive, they also underscore the importance of preparedness, including clear cross-department communication, supplier diversification, and data-driven inventory management. With the right tools and insight, organizations can respond strategically rather than reactively. Staritas partners with healthcare organizations to navigate disruptions like this one by turning uncertainty into informed action and helping ensure patient care continues without compromise. Explore how Staritas Functional Equivalents and Recall Management solutions can help you quickly identify appropriate alternatives, assess risk exposure, and respond to disruptions with clarity and confidence.
Medline receives FDA warning letter on its heart procedure syringes. April 09, 2026 01:29 PM CDT The Food and Drug Administration has sent a warning letter to Medline Industries over reported issues with syringes used in cardiac procedures and the company could face regulatory action if the issues are not corrected. Staying current is easy with newsletters delivered straight to your inbox.